2 The predisposition to T1DM is polygenic 1 and several 'susceptibility genes' that predispose to ␤-cells destruction by cytokine-mediated mechanisms have been suggested, including genes involved in apoptosis.
Type 1 diabetes mellitus (T1DM) is the result of a selective destruction of pancreatic islet ␤ cells. 1 Both necrotic and programmed cell death (apoptotic) pathways of ␤-cell death have been suggested in vivo and demonstrated in vitro. 2 The predisposition to T1DM is polygenic 1 and several 'susceptibility genes' that predispose to ␤-cells destruction by cytokine-mediated mechanisms have been suggested, including genes involved in apoptosis.
BCL2 plays a key role in the regulation of apoptosis. 3 This has led to investigations focused on the BCL2 as a candidate gene and/or protein in autoimmunity. 4, 5 It has been speculated that variants, ie polymorphisms, of BCL2 can lead to modifications of anti-apoptotic function, ie an imbalance of cell homeostasis in general. IL-1␤, TNF-␣ and IFN-␥ are mediators of ␤-cell destruction 1 and insufficient negative selection of the cells responsible for cytokine secretion in the pancreatic islets could be a result of BCL2 variants. It has been suspected that defective elimination of auto-reactive T cells is a central mechanism in the development of autoimmune diseases. 5 Alternatively, the ␤ cell could become more sensitive to cytokinemediated apoptosis if carrying a BCL2 polymorphism, thereby increasing an individual's risk of developing T1DM.
Search for mutations/polymorphisms in the human BCL2 gene with association to autoimmunity, previously led to the identification of a single nucleotide polymorphism (SNP), G→A in the coding region of BCL2 (exon 2) resulting in an Ala43Thr substitution. 6 The polymorphism was reported to be frequent in the Japanese population compared to a group of Japanese T1DM patient as well as to patients with other autoimmune diseases, ie systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). 6 Furthermore, functional studies demonstrated that an overexpression of the specific 43Thr BCL2 protein in an IL-7 dependent mouse pre-B cell line made them more sensitive to apoptosis during IL-7 depletion. These findings suggest that this BCL2 polymorphism, which is the first reported with association to T1DM, confers some resistance against T1DM and to autoimmunity in general.
The aim of the present study was to investigate the frequency of the BCL2 Ala43Thr polymorphism in a population of Danish, Finnish and Basque Caucasians with familial T1DM and test for association to T1DM. The Finnish and Basque populations were selected as they represent isolated populations. In addition, the T1DM incidence in Finland is the highest known.
We studied three Caucasoid T1DM populations comprising: 257 Danish families (1143 individuals), Finnish sibling pairs (175 individuals), and a test panel of 50 Basque individuals, described in details elsewhere. [7] [8] [9] DNA-genotyping was made using a two-step polymerase chain reaction (PCR) based assay, followed by Bgl1 restriction endonuclease digestion. 6 After the Bgl1 digest the fragments were separated on a 2% agarose gel. In addition, the three possible control genotypes were constructed by mutagenesis and evaluated in the screening assay. These data were also confirmed by direct sequencing ( Figure 1 ).
The study revealed that the reported BCL2 SNP was not present in the Danish, the Finnish, or the Basque collections at all, ie, 1371 individuals were homozygous for the wild-type allele. This is in strong contrast to observations in the Japanese population. The absence of the mutation in the investigated populations is unlikely to be due to methodological causes, since introduction of the mutation by a mutagenesis approach clearly revealed that the assay used easily detected the G→A transistion. The study by Komaki et al 6 included, the genotyping of 221 Japanese T1DM patients and 290 control individuals and revealed that the polymorphism was frequent (14.5%) in the control group. Interestingly, the frequency of the polymorphism was found to be significantly lower in Japanese T1DM patients (6.8%). The observed difference between Danish Caucasians and Japanese is striking and surprising as one would not expect allele frequencies Ͼ10% to be population-specific. 10 However, we can rule out that the Ala43Thr variation exists in the Danish, Finnish and Basque populations with frequencies higher than 0.5% in both diabetic as well as non-diabetic subjects.
Interestingly, a very recent study searching for SNPs in the BCL2 gene, using a panel of Mexican Mestizos and Swedish control subjects, did not find the Ala43Thr variation in these populations either.
11 Despite these observations, BCL2 cannot be excluded as a candidate gene for T1DM. Variations in other parts of the gene may show association to T1DM. In fact, the BCL2 gene maps to the human chromosome 18q21, which is within the region of the T1DM candidate locus IDDM6 (18q12-q21). 12 It is likely that the pathogenesis and the clinical progress of T1DM may differ between Japanese and Caucasians and furthermore, T1DM occurs with significantly lower frequency in Japan. It is likely that the Ala43Thr polymorphism arose spontaneously in Asians/Japanese after the human ancestor population separated into CauGenes and Immunity casians and Asians in the early history of Man. The event of random mutations, might, due to selection and genetic drift have led to genetic heterogeneity in respect of disease pathogenesis. This will of course represent a major limitation when using multi-ethnic populations in studies of multifactorial diseases.
Accumulating evidence suggest that autoimmune diseases share common features, 13, 14 and an effect of BCL2 dysfunction is evident in autoimmune diseases other than T1DM. 6 In this context, overexpression of BCL2 has been found in both man and in mouse models of SLE. 15 A recent study of Mexican American SLE patients showed independent risk of development of SLE, when carrying specific genotypes of either BCL2 or IL-10. In combination, these two gene polymorphisms increased the risk, by more than 40-fold. 16 Several studies have illustrated the anti-apoptotic effect of the BCL2 protein in ␤ cells (human and rodents). An overexpression of human BCL2 protein in a mouse ␤TC1 ␤-cell line made them partially resistance to apoptosis when incubated with a combination of the cytokines: IL-1␤, TNF-␣ and IFN␥. 17 Rabinovitch et al 18 demonstrated protection of ␤ cells (human islets) tranfected with human BCL2 when exposed to a mixture of destructive cytokines (IL-␤, TNF-␣ and IFN-␥). These studies demonstrated the protective features of BCL2 in ␤ cells, and illustrate a quantitative effect due to an overexpression. Taken together, these data suggest that the BCL2 product has a potential protective effect in vitro and in vivo, which stresses its 'candidate gene' status in the context of T1DM pathogenesis. Still, it has to be demonstrated whether any BCL2 polymorphism promotes its effect in the ␤ cell directly or through a malfunction in T-cell selection. The BCL2 polymorphism data found in Japanese 6 tend to support the later thesis, since it appears to add resistance to autoimmune diseases other than T1DM. However, this variant was not found in our T1DM material, indicating that this BCL2 variant is not relevant for the development of T1DM in Danish, Finnish and Basque Caucasians, but rather represent a population-specific susceptibility factor.
The DNA used for the study was purified by standard procedures. 19 For analysis of the Ala43Thr SNP in the BCL2 gene (exon 2) a restriction fragment length polymorphism (RFLP) assay, consisting of two separate PCRs, ie, a nested PCR, followed by Bgl1 endonuclease digestion, was performed. Conditions for the first PCR (PCR1) were as follows: Denaturation at 95°C for 30 s, annealing at 63°C for 30 s, and extension at 72°C for 30 s. Sequence of primers used for PCR1: (forward/reverse, 5Ј→3Ј) TGGGGTGGGAGC-TGGGGCGAGAG/GGTCAGCAGC GGCGAGGTCC, which yields a 281-bp product. The second PCR (PCR2) was performed using PCR1 product (diluted × 100) as template DNA. The reaction conditions were as follows: denaturation at 95°C for 30 s, annealing at 62°C for 30 s, and extension at 72°C for 30 s. Sequence of primers used for PCR2: (forward/reverse, 5Ј→3Ј) CCCGTTGCTTTTCCTCTGGGA/GGGAGGAGAAGATG CCCGCCGCGGGG, resulting in a 178-bp amplicon. The PCR2 amplicons were incubated over night with BglI enzyme, which results in a complete digestion of the wildtype homozygote, ie, the Ala43 genotype (157-bp + 21-bp) and mutant homozygote, ie, the Thr43 genotype undigested (178-bp), respectively. Genotype identification was completed on a 2% agarosegel. By site directed mutagenesis, one of each genotype (Ala43, Thr43 and Ala/Thr43) was generated, for assay evaluation. DNA from two individuals (Ala43) was subjected to PCR1. Three samples of each PCR1 product (× 100 diluted) were subjected to individual PCR's (PCRA, -B and -C), only differing in respect of the sequence/combination of the reverse primer. The forward primer was identical to the one used as forward primer in PCR2. PCR conditions were in all three cases as for PCR1. The sequence of the reverse primer used for PCRA: (5Ј→3Ј) GGGAGGAGAAGATGCCCGGTGCGG GGGCGGCCCCC, PCRC: GGGAGGAGAAGATGCC CGGTGCGGGGGTGGCCCCC and, PCRB: a 1:1 mixture of the two, generating the Ala43, Thr43 and Ala/Thr43 genotype, respectively. The three samples were diluted × 100, and subjected to PCR2 and finally digested by BglI enzyme. For additional verification of the PCR products constituting the three genotypes, they were subjected to direct sequencing. The three DNA samples (PCR2A, B and C) were purified using a spin-out procedure, and sequences using primers identical to those used in PCR2. Both the mutagenesis and sequencing approach confirmed that the RFLP assay was functional and reliable ( Figure 1 ).
